Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

Open Access Highly Accessed Viewpoints

Multiple choices for HIV therapy with integrase strand transfer inhibitors

Francois Raffi1 and Mark A Wainberg2*

Author Affiliations

1 University Hospital of Nantes, EA 4271, 1 Place Ricordeau, Nantes cedex 1 44093, France

2 McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Côte-Sainte-Catherine Rd, Montreal, QC H3T 1E2, Canada

For all author emails, please log on.

Retrovirology 2012, 9:110  doi:10.1186/1742-4690-9-110

Published: 19 December 2012

Abstract

Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens.

Keywords:
Raltegravir; Elvitegravir; Dolutegravir; Integrase strand transfer inhibitors